Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cancer
    • Metformin prevents...

    Metformin prevents endometriosis in breast cancer patients

    Written by Medha Baranwal Baranwal Published On 2018-12-05T19:15:06+05:30  |  Updated On 5 Dec 2018 7:15 PM IST
    Metformin prevents endometriosis in breast cancer patients

    Australia: Metformin appears to prevent endometrial changes induced by tamoxifen, and has favorable metabolic effects in breast cancer patients, according to a new study published in the journal Clinical Endocrinology.


    Susan R. Davis, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia, and colleagues conducted this randomized placebo-controlled trial to determine whether metformin prevents tamoxifen‐induced endometrial changes and insulin resistance (IR) after a breast cancer diagnosis.


    Also Read: 3D mammography more effective for breast cancer screening

    Tamoxifen is an endocrine therapy used for the treatment of breast cancer. Although an estrogen antagonist in the breast, tamoxifen is an estrogen agonist in the endometrium. The mean endometrial thickness (ET) has been reportedly known to increase in the first year of tamoxifen, it is also associated with endometrial hyperplasia (EH), endometrial polyps, and endometrial cancer. Compared with nonuse of the drug after breast cancer, its use causes 2– to 7–fold increase in the risk of endometrial cancer after 2 and 5 years of tamoxifen treatment.


    For the study, 102 postmenopausal women with hormone receptor-positive breast cancer taking tamoxifen were randomized to receive metformin 850 mg or identical placebo, twice daily, for 52 weeks. The 101 women who took at least one dose of medication were aged 56 (43–72) years, with 5(0.5–28) years postmenopause, and had taken tamoxifen for 28.9 (0–367.4) weeks.


    Outcome measures included a double endometrial thickness (ET) measured by transvaginal ultrasound, fasting insulin, glucose and IR estimated by the homeostasis model of assessment (HOMA-IR).


    Also Read: 85% women at high risk of breast cancer avoid preventive tamoxifen

    Key Findings:




    • The baseline ET was 2.9 mm (1.4–21.9) for the placebo group (n = 52) and 2.5 mm (1.3–14.8) for the metformin group (n = 50).

    • At 52 weeks, the median ET was statistically significantly lower for the metformin (n = 36) than for the placebo group (n = 45) (2.3 mm (1.4–7.8) vs 3.0 (1.2–11.3); P = 0.05).

    • 13.3% allocated to placebo had an ET greater than 4 mm vs 5.7% for metformin.

    • There was no endometrial atypia or cancer.

    • Compared with placebo, metformin resulted in significantly greater baseline-adjusted reductions in weight, waist circumference (0.03) and HOMA-IR.


    "Further research into the adjuvant use of metformin after breast cancer and to prevent EH and cancer is warranted," concluded the authors.


    For further reference follow the link: https://doi.org/10.1111/cen.13830
    breast cancerClinical Endocrinologyendometrial cancersendometrial changesendometrial hyperplasiaendometrial polypsendometriosisHOMA IRinducedinsulin resistancemetforminSusan DavisTamoxifentreatment
    Source : With inputs from Clinical Endocrinology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok